AGEN
Price
$4.20
Change
-$0.03 (-0.71%)
Updated
Nov 19 closing price
Capitalization
143.11M
Intraday BUY SELL Signals
CLDX
Price
$24.93
Change
-$0.65 (-2.54%)
Updated
Nov 19, 04:59 PM (EDT)
Capitalization
1.66B
102 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

AGEN vs CLDX

Header iconAGEN vs CLDX Comparison
Open Charts AGEN vs CLDXBanner chart's image
Agenus
Price$4.20
Change-$0.03 (-0.71%)
Volume$267.95K
Capitalization143.11M
Celldex Therapeutics
Price$24.93
Change-$0.65 (-2.54%)
Volume$11.59K
Capitalization1.66B
AGEN vs CLDX Comparison Chart in %
AGEN
Daily Signal:
Gain/Loss:
CLDX
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
AGEN vs. CLDX commentary
Nov 20, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AGEN is a Hold and CLDX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 20, 2025
Stock price -- (AGEN: $4.21 vs. CLDX: $24.92)
Brand notoriety: AGEN and CLDX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AGEN: 60% vs. CLDX: 90%
Market capitalization -- AGEN: $143.11M vs. CLDX: $1.66B
AGEN [@Biotechnology] is valued at $143.11M. CLDX’s [@Biotechnology] market capitalization is $1.66B. The market cap for tickers in the [@Biotechnology] industry ranges from $106.82B to $0. The average market capitalization across the [@Biotechnology] industry is $2.12B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AGEN’s FA Score shows that 0 FA rating(s) are green whileCLDX’s FA Score has 0 green FA rating(s).

  • AGEN’s FA Score: 0 green, 5 red.
  • CLDX’s FA Score: 0 green, 5 red.
According to our system of comparison, both AGEN and CLDX are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AGEN’s TA Score shows that 6 TA indicator(s) are bullish while CLDX’s TA Score has 6 bullish TA indicator(s).

  • AGEN’s TA Score: 6 bullish, 2 bearish.
  • CLDX’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, AGEN is a better buy in the short-term than CLDX.

Price Growth

AGEN (@Biotechnology) experienced а -5.01% price change this week, while CLDX (@Biotechnology) price change was +2.76% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.19%. For the same industry, the average monthly price growth was -5.74%, and the average quarterly price growth was +63.93%.

Reported Earning Dates

CLDX is expected to report earnings on Mar 02, 2026.

Industries' Descriptions

@Biotechnology (-2.19% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CLDX($1.66B) has a higher market cap than AGEN($143M). AGEN YTD gains are higher at: 53.577 vs. CLDX (-1.385). AGEN has higher annual earnings (EBITDA): -74.93M vs. CLDX (-231.4M). CLDX has more cash in the bank: 630M vs. AGEN (9.53M). CLDX has less debt than AGEN: CLDX (3.03M) vs AGEN (90.5M). AGEN has higher revenues than CLDX: AGEN (102M) vs CLDX (5.79M).
AGENCLDXAGEN / CLDX
Capitalization143M1.66B9%
EBITDA-74.93M-231.4M32%
Gain YTD53.577-1.385-3,868%
P/E Ratio0.16N/A-
Revenue102M5.79M1,762%
Total Cash9.53M630M2%
Total Debt90.5M3.03M2,986%
FUNDAMENTALS RATINGS
AGEN vs CLDX: Fundamental Ratings
AGEN
CLDX
OUTLOOK RATING
1..100
1567
VALUATION
overvalued / fair valued / undervalued
1..100
94
Overvalued
68
Overvalued
PROFIT vs RISK RATING
1..100
10081
SMR RATING
1..100
10094
PRICE GROWTH RATING
1..100
4448
P/E GROWTH RATING
1..100
97100
SEASONALITY SCORE
1..100
5040

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CLDX's Valuation (68) in the Biotechnology industry is in the same range as AGEN (94). This means that CLDX’s stock grew similarly to AGEN’s over the last 12 months.

CLDX's Profit vs Risk Rating (81) in the Biotechnology industry is in the same range as AGEN (100). This means that CLDX’s stock grew similarly to AGEN’s over the last 12 months.

CLDX's SMR Rating (94) in the Biotechnology industry is in the same range as AGEN (100). This means that CLDX’s stock grew similarly to AGEN’s over the last 12 months.

AGEN's Price Growth Rating (44) in the Biotechnology industry is in the same range as CLDX (48). This means that AGEN’s stock grew similarly to CLDX’s over the last 12 months.

AGEN's P/E Growth Rating (97) in the Biotechnology industry is in the same range as CLDX (100). This means that AGEN’s stock grew similarly to CLDX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AGENCLDX
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
73%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
83%
Bearish Trend 2 days ago
84%
Momentum
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 2 days ago
82%
MACD
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 2 days ago
81%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 2 days ago
80%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 8 days ago
85%
Bullish Trend 3 days ago
81%
Declines
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 7 days ago
78%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 2 days ago
83%
Aroon
ODDS (%)
N/A
Bullish Trend 2 days ago
73%
View a ticker or compare two or three
Interact to see
Advertisement
AGEN
Daily Signal:
Gain/Loss:
CLDX
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BTGOF2.340.09
+3.78%
BT Group Plc
WTRNF0.01N/A
N/A
Western Resources Corp.
CDPYF27.22-0.29
-1.05%
Canadian Apartment Properties Real Estate Investment Trust
MALJF12.05-0.23
-1.89%
Magellan Aerospace Corporation
EEMMF0.68-0.02
-2.18%
E3 LITHIUM LTD.